Halothane hepatitis.
Halothane, an effective and usually safe anaesthetic agent, is rarely associated with the development of fulminant hepatic failure. Guidelines have been developed to reduce the probability of a patient developing halothane hepatitis. However, cases continue to occur and, in some cases, the guidelines have been ignored. Stricter adherence to the guidelines will reduce, but not totally prevent, further cases from occurring. Once halothane hepatitis has developed, there are no specific treatments and liver replacement may be required. Halothane hepatitis is a paradigm for immune mediated adverse drug reactions. The mechanism appears to be related to development of sensitization to both autoantigens (including CYP2D6) and halothane-altered liver cell determinants.
Neuberger
J
J
Queen Elizabeth Hospital, Birmingham, UK. j.m.neuberger@bham.ac.uk
D018685:Anesthetics, Inhalation / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology* / Q000601:surgery; D019983:Guideline Adherence; D006221:Halothane / Q000009:adverse effects*; D006801:Humans; D016031:Liver Transplantation
D018685:Anesthetics, Inhalation; D006221:Halothane